Budget Amount *help |
¥185,380,000 (Direct Cost: ¥142,600,000、Indirect Cost: ¥42,780,000)
Fiscal Year 2020: ¥30,680,000 (Direct Cost: ¥23,600,000、Indirect Cost: ¥7,080,000)
Fiscal Year 2019: ¥33,410,000 (Direct Cost: ¥25,700,000、Indirect Cost: ¥7,710,000)
Fiscal Year 2018: ¥33,020,000 (Direct Cost: ¥25,400,000、Indirect Cost: ¥7,620,000)
Fiscal Year 2017: ¥32,110,000 (Direct Cost: ¥24,700,000、Indirect Cost: ¥7,410,000)
Fiscal Year 2016: ¥56,160,000 (Direct Cost: ¥43,200,000、Indirect Cost: ¥12,960,000)
|
Outline of Final Research Achievements |
The immune response requires a mechanism to control the excessive immune response. The purpose of this study was to understand the negative regulatory mechanism of the innate immune response by dendritic cells, macrophages, neutrophils, mast cells, and to elucidate the significance of inhibitory immune receptors in the innate immune response. In this study, we identified the ligands of CD300a, Allergin-1, and Clec10a. In addition, binding of these inhibitory receptors to their respective ligands suppressed FceRI;RI, TLR2, and TLR4 signals via tyrosine phosphatase SHP-1, and inhibited activation of mast cells, dendritic cells, macrophages. As a result, they control allergic and inflammatory pathologies in organs such as skin, airway, and intestinal tract. Therefore, these inhibitory receptors can be target molecules for these diseases.
|